Safety and metabolic effects of tesamorelin, a growth hormone-releasing factor analogue, in patients with type 2 diabetes: A randomized, placebo-controlled trial

OBJECTIVE: Use of growth hormone is associated with side effects, including insulin resistance. The objective of this study was to determine whether tesamorelin, a stabilized growth hormone-releasing hormone analogue, would alter insulin sensitivity or control of diabetes. DESIGN: A 12-week randomiz...

Descripción completa

Detalles Bibliográficos
Autores principales: Clemmons, David R., Miller, Sam, Mamputu, Jean-Claude
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5472315/
https://www.ncbi.nlm.nih.gov/pubmed/28617838
http://dx.doi.org/10.1371/journal.pone.0179538

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5472315/
https://www.ncbi.nlm.nih.gov/pubmed/28617838
http://dx.doi.org/10.1371/journal.pone.0179538

Ejemplares similares